Journal of the American Society of Hypertension
Volume 2, Issue 4, Supplement , Pages S30-S37 , July 2008

Slowing the progression of kidney disease in patients with diabetes

Based on material presented at a Boehringer Ingelheim-Sponsored Meeting held in Madrid, Spain, May 4–5, 2007.

  • Ellen Burgess, MD

      Affiliations

    • Corresponding Author InformationCorresponding author: Ellen Burgess, MD, University of Calgary, 1403-29 Street NW, Calgary, Alberta, T2N 2T9 Canada. Tel: 001 403 944 1598; fax: 001 403 283 2494.

  • Image Result

    The typical course of diabetic nephropathy. Reproduced with permission from Pylypchuk G, Beaubien E. Diabetic nephropathy. Prevention and early referral. Can Fam Physician 2000;46:636–42.12

    The typical course of diabetic nephropathy. Reproduced with permission from Pylypchuk G, Beaubien E. Diabetic nephropathy. Prevention and early referral. Can Fam Physician 2000;46:636–42.12

  • Image Result

    The effect of the degree of proteinuria on the risk of cardiovascular mortality (Left) and stroke or CHD events (Right) in patients with type 2 diabetes. CHD, coronary heart disease; U-Prot, urinary p

    The effect of the degree of proteinuria on the risk of cardiovascular mortality (Left) and stroke or CHD events (Right) in patients with type 2 diabetes. CHD, coronary heart disease; U-Prot, urinary protein concentration. Reproduced with permission from Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996;27:2033–39.21

  • Image Result
    Annual transition rates in diabetic nephropathy: results of the United Kingdom Prospective Diabetes Study (UKPDS 64). Reproduced with permission from Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull C

    Annual transition rates in diabetic nephropathy: results of the United Kingdom Prospective Diabetes Study (UKPDS 64). Reproduced with permission from Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holmes RR, UKPDS Group. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225–32.25

  • Image Result
    Effect of irbesartan 150 or 300 mg or placebo on changes in UAE rate during and after discontinuation of treatment in patient with type 2 diabetes and microalbumurinia. UAE, urinary albumin excretion.

    Effect of irbesartan 150 or 300 mg or placebo on changes in UAE rate during and after discontinuation of treatment in patient with type 2 diabetes and microalbumurinia. UAE, urinary albumin excretion. © 2003 American Diabetes Association. Reprinted with permission from Andersen S, Brochner-Mortensen J, Parving H-H, Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care 2003;26:3296–302.28

  • Image Result
    Effect of telmisartan 40 or 80 mg or placebo on the transition from microalbuminuria to overt nephropathy in Japanese patient with type 2 diabetes and with or without hypertension. NNT, number needed

    Effect of telmisartan 40 or 80 mg or placebo on the transition from microalbuminuria to overt nephropathy in Japanese patient with type 2 diabetes and with or without hypertension. NNT, number needed to treat to prevent one transition; RRR, relative risk reduction. © 2007 American Diabetes Association. Reprinted with permission from Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007;30:1577–8.29

 Conflict of interest: none.

PII: S1933-1711(08)00042-9

doi: 10.1016/j.jash.2008.03.007

Journal of the American Society of Hypertension
Volume 2, Issue 4, Supplement , Pages S30-S37 , July 2008

Article Tools

* Image Usage & Resolution